FULMINATING MYELOGENOUS LEUKAEMIA

Chronic myelogenous leukaemia (CML)

Evidence exists for the involvement of the most primitive and quiescent hematopoietic stem cell compartiment (CD34+/CD38-, Thy1+): t(9;22) is found in myeloid progenitor and in B-lymphocytes progenitors, but, involvement of the T-cell lineage is extremely rare. The existence of a highly quiescent stem cell population has been demonstrated in patients with CML. More recently, the presence of Ph ...

Chronic myelogenous leukaemia (CML)

Clinics Splenomegaly; chronic phase (lasts about 3 yrs) with maintained cell’s normal activities, followed by accelerated phase(s)(blasts still < 15%), and blast crisis (BC-CML) with blast cells > 30%; blood data: WBC: 100 X 10/l and more during chronic phase, with basophilia; a few blasts; thrombocytosis may be present; low leucocyte alkaline phosphatases; typical acute leukaemia (AL) blood da...

Chronic myelogenous leukaemia in infancy.

Chronic myelogenous leukaemia is an uncommon disease in infancy and is usually termed congenital in cases seen at or within a few days after birth. The latter do not appear to differ from those seen later except that they are believed to have started during intra-uterine life, and Kelsey and Andersen (1939) have laid down certain criteria for the diagnosis, which might be briefly stated as symp...

Ovarian sarcoma and acute myelogenous leukaemia.

VP 16-213 in acute myelogenous leukaemia.

The use of the epipodophyllotoxin VP 16-213 is described in twenty patients with acute myelogenous leukaemia resistant to other chemotherapy. The drug was usually given in 5-day courses of 50 mg/M2 daily and occasionally in 24-hr infusions of 250 mg/M2, on the basis of its phase-activity. Complete remission was achieved in only two patients: in one of these, remission was maintained with VP 16-...